Januvia Class Action lant foods present a double-edged sword, since they contain both cancer-causing and cancer-preventing com­pounds. Vegetables provide vitamins such as A, C, and E, which neutralize some important carcinogens, notably die oxidants and free radicals generated during normal cell me­tabolism. On the other hand, some plant components may actively contribute to cancer. Plants have evolved elaborate chemical defense systems to make themselves unpalatable to insect predators. Among these are compounds that are regis­tered as potent mutagens in the Ames test. Ames himself has cited the case of a new strain of celery that was bred to re­quire less synthetic insecticide during its cultivation; the in­creased insect resistance shown by this celery correlated with a tenfold increase in a potent mutagen that is found nat­urally in this vegetable.

Early detection of tumors will prove increasingly impor­tant. The discovery and removal of a tumor mass in its initial stages often results in a cure. But early detection presents two major difficulties. First, nests of cancer cells must be discovered while they are still very small. As we saw earlier, a tumor of one centimeter diameter constitutes less than 0.01 percent of the body’s mass. Few currently available biochem­ical assays are sensitive enough to detect such minute enti­ties. Second, cancer cells, especially those in the early stages of tumor progression, are in almost all respects very much like normal cells. The task of finding distinctive markers that are specific to cancer cells is daunting. Almost all proteins that have been proclaimed “tumor-specific” have later been found to be produced also by normal tissues somewhere in the body.

Familial tumors also contribute to a substantial fraction of human cancer incidence. Some researchers estimate that as much as 10 percent of all human cancer derives from inher­ited genes. The ability to predict inborn susceptibility to can­cer thus represents another highly useful dimension of early detection. The technology for detecting mutant genes in small tissue samples is improving rapidly. Soon, a mutant inherited gene predisposing an individual to one or another cancer will be readily detectable using only several chops of that person’s blood. Similar analyses will be available for prenatal diagno­sis, to be used in families known to be afflicted with unusu­ally high rates of certain cancers. These tests will identify those members of a family who are at high risk and those who are spared that risk. Family members who are found to be at risk will need to be monitored throughout their lives. In the case of especially life-threatening conditions, including familial polyposis and breast cancer, the patient may decide to have the target organ removed before a malignant tumor appears.

Our use of the term or terms Januvia Class Action is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Januvia Class Action News visit our site often.

Januvia Class Action